CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PRIME project aims to enhance cancer treatment by developing a prodrug platform for at-home administration of chemotherapy. This approach focuses on low-dose, high-frequency dosing to improve immune responses in patients with breast and prostate cancer, making treatment more accessible and effective.
Immunotherapy holds great promise for curative cancer treatment.
While immune checkpoint inhibitors can induce complete and long-term cures, the percentage of patients responding to immunotherapy remains to be low.
Combining immunotherapy with chemotherapeutic drugs that induce immunogenic cell death (ICD) is among the most promising strategies to potentiate antitumor immune responses.
Chemotherapeutics are clinically typically administered via intravenous infusion, once every couple of weeks, a…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
